These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 32668412

  • 1. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
    Li J, Zhang Y, Hu D, Gong T, Xu R, Gao J.
    Aging (Albany NY); 2020 Jul 15; 12(14):14271-14284. PubMed ID: 32668412
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
    Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K.
    ESMO Open; 2023 Feb 15; 8(1):100762. PubMed ID: 36610262
    [Abstract] [Full Text] [Related]

  • 3. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
    Matsusaka K, Ushiku T, Urabe M, Fukuyo M, Abe H, Ishikawa S, Seto Y, Aburatani H, Hamakubo T, Kaneda A, Fukayama M.
    Oncotarget; 2016 Sep 27; 7(39):64168-64181. PubMed ID: 27580354
    [Abstract] [Full Text] [Related]

  • 4. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer.
    Matsuishi A, Nakajima S, Saito M, Saito K, Fukai S, Tsumuraya H, Kanoda R, Kikuchi T, Nirei A, Kaneta A, Okayama H, Mimura K, Hanayama H, Sakamoto W, Momma T, Saze Z, Kono K.
    Sci Rep; 2024 Aug 02; 14(1):17916. PubMed ID: 39095563
    [Abstract] [Full Text] [Related]

  • 5. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, Yuan L, Ma Y.
    BMC Gastroenterol; 2023 Aug 16; 23(1):283. PubMed ID: 37582713
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
    Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Türeci Ö.
    Jpn J Clin Oncol; 2019 Sep 01; 49(9):870-876. PubMed ID: 31087075
    [Abstract] [Full Text] [Related]

  • 7. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
    Dottermusch M, Krüger S, Behrens HM, Halske C, Röcken C.
    Virchows Arch; 2019 Nov 01; 475(5):563-571. PubMed ID: 31332522
    [Abstract] [Full Text] [Related]

  • 8. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
    Nakayama I, Shinozaki E, Sakata S, Yamamoto N, Fujisaki J, Muramatsu Y, Hirota T, Takeuchi K, Takahashi S, Yamaguchi K, Noda T.
    Cancer Sci; 2019 Apr 01; 110(4):1352-1363. PubMed ID: 30771244
    [Abstract] [Full Text] [Related]

  • 9. REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype.
    Yu J, Liang Q, Wang J, Wang K, Gao J, Zhang J, Zeng Y, Chiu PW, Ng EK, Sung JJ.
    Oncogene; 2017 Jan 12; 36(2):182-193. PubMed ID: 27212034
    [Abstract] [Full Text] [Related]

  • 10. Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling.
    Xu X, Li Y, Zhang R, Chen X, Shen J, Yuan M, Chen Y, Chen M, Liu S, Wu J, Sun Q.
    J Ethnopharmacol; 2023 Jul 15; 311():116450. PubMed ID: 37023839
    [Abstract] [Full Text] [Related]

  • 11. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
    Baek JH, Park DJ, Kim GY, Cheon J, Kang BW, Cha HJ, Kim JG.
    Anticancer Res; 2019 Dec 15; 39(12):6973-6979. PubMed ID: 31810969
    [Abstract] [Full Text] [Related]

  • 12. Ultrasensitive Gastric Cancer Circulating Tumor Cellular CLDN18.2 RNA Detection Based on a Molecular Beacon.
    Fan L, Chong X, Zhao M, Jia F, Wang Z, Zhou Y, Lu X, Huang Q, Li P, Yang Y, Hu Z, Li Q, Zhang X, Shen L.
    Anal Chem; 2021 Jan 19; 93(2):665-670. PubMed ID: 33314914
    [Abstract] [Full Text] [Related]

  • 13. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
    Dai J, Zheng H, Jin J, Cheng Y, Xu H.
    Cancer Cytopathol; 2023 Jun 19; 131(6):365-372. PubMed ID: 36793190
    [Abstract] [Full Text] [Related]

  • 14. Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach.
    Hagen SJ, Ang LH, Zheng Y, Karahan SN, Wu J, Wang YE, Caron TJ, Gad AP, Muthupalani S, Fox JG.
    Gastroenterology; 2018 Dec 19; 155(6):1852-1867. PubMed ID: 30195448
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer.
    Shu Y, Zhang W, Hou Q, Zhao L, Zhang S, Zhou J, Song X, Zhang Y, Jiang D, Chen X, Wang P, Xia X, Liao F, Yin D, Chen X, Zhou X, Zhang D, Yin S, Yang K, Liu J, Fu L, Zhang L, Wang Y, Zhang J, An Y, Cheng H, Zheng B, Sun H, Zhao Y, Wang Y, Xie D, Ouyang L, Wang P, Zhang W, Qiu M, Fu X, Dai L, He G, Yang H, Cheng W, Yang L, Liu B, Li W, Dong B, Zhou Z, Wei Y, Peng Y, Xu H, Hu J.
    Nat Commun; 2018 Jun 30; 9(1):2447. PubMed ID: 29961079
    [Abstract] [Full Text] [Related]

  • 16. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    Tao D, Guan B, Li Z, Jiao M, Zhou C, Li H.
    Pathol Res Pract; 2023 Aug 30; 248():154699. PubMed ID: 37487317
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression.
    Kwak Y, Kim TY, Nam SK, Hwang HJ, Han D, Oh HJ, Kong SH, Park DJ, Oh DY, Lee HJ, Im SA, Yang HK, Lee HS.
    Oncologist; 2024 Sep 21. PubMed ID: 39306800
    [Abstract] [Full Text] [Related]

  • 18. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.
    Int J Cancer; 2014 Nov 01; 135(9):2206-14. PubMed ID: 24710653
    [Abstract] [Full Text] [Related]

  • 19. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
    Zhang F, Sahu V, Peng K, Wang Y, Li T, Bala P, Aitymbayev D, Sahgal P, Schaefer A, Der CJ, Ryeom S, Yoon S, Sethi N, Bass AJ, Zhang H.
    Gut; 2024 Jul 11; 73(8):1280-1291. PubMed ID: 38621923
    [Abstract] [Full Text] [Related]

  • 20. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype.
    Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W.
    J Pathol; 2006 Apr 11; 208(5):633-42. PubMed ID: 16435283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.